



# Antiuro lithic effects of medicinal plants: results of in vivo studies in rat models of calcium oxalate nephrolithiasis—a systematic review

Aslam Khan<sup>1,2</sup> · Samra Bashir<sup>3</sup> · Saeed R. Khan<sup>4</sup>

Received: 17 July 2020 / Accepted: 17 December 2020 / Published online: 23 January 2021  
© The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature 2021

## Abstract

Urolithiasis is one of the oldest diseases affecting humans, while plants are one of our oldest companions providing food, shelter, and medicine. In spite of substantial progress in understanding the pathophysiological mechanisms, treatment options are still limited, often expensive for common people in most parts of the world. As a result, there is a great interest in herbal remedies for the treatment of urinary stone disease as an alternative or adjunct therapy. Numerous in vivo and in vitro studies have been carried out to understand the efficacy of herbs in reducing stone formation. We adopted PRISMA guidelines and systematically reviewed PubMed/Medline for the literature, reporting results of various herbal products on in vivo models of nephrolithiasis/urolithiasis. The Medical Subject Heading Terms (Mesh term) “Urolithiasis” was used with Boolean operator “AND” and other related Mesh Unique terms to search all the available records (July 2019). A total of 163 original articles on in vivo experiments were retrieved from PubMed indexed with the (MeshTerm) “Urolithiasis” AND “Complementary Therapies/Alternative Medicine, “Urolithiasis” AND “Plant Extracts” and “Urolithiasis” AND “Traditional Medicine”. Most of the studies used ethylene glycol (EG) to induce hyperoxaluria and nephrolithiasis in rats. A variety of extraction methods including aqueous, alcoholic, hydro-alcoholic of various plant parts ranging from root bark to fruits and seeds, or a combination thereof, were utilized. All the investigations did not study all aspects of nephrolithiasis making it difficult to compare the efficacy of various treatments. Changes in the lithogenic factors and a reduction in calcium oxalate (CaOx) crystal deposition in the kidneys were, however, considered favorable outcomes of the various treatments. Less than 10% of the studies examined antioxidant and diuretic activities of the herbal treatments and concluded that their antiuro lithic activities were a result of antioxidant, anti-inflammatory, and/or diuretic effects of the treatments.

**Keywords** Kidney stones · Calcium oxalate · Urolithiasis · Nephrolithiasis · Medicinal plants · Herbal medicine · Traditional medicine

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00240-020-01236-0>.

✉ Saeed R. Khan  
khan@pathology.ufl.edu

- <sup>1</sup> College of Science and Health Professions, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
- <sup>2</sup> King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- <sup>3</sup> Department of Pharmacy, Faculty of Health and Life Sciences, Capital University of Science and Technology, Islamabad, Pakistan
- <sup>4</sup> Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA

## Introduction

Urolithiasis, the development of stones/crystals in the urinary tract, has been affecting humans since the dawn of history, as evident from the discovery of kidney and bladder stone in Egyptian mummies [1]. Estimated lifetime risk of urolithiasis around 2–5% in Asia, 8–15% in America and Europe, and about 20% in the Middle East [2]. It is estimated that in the United States, the population living in high-risk zones for nephrolithiasis will grow from 40% in 2000 to 56% by 2050, and to 70% by 2095 [3]. These projections highlight the need for finding ways to reduce the occurrence of this disease and less costly tests and treatments. In addition, the age of onset is decreasing and the annual incidence of urolithiasis is increasing, which can be linked to changes in climate, lifestyles, and diets [4]. The rate of recurrence is

also increasing. After one year of the first episode the rate of urolithiasis recurrence is around 10–23%, within 5–10 years it is around 50% and 75% in 20 years. After every episode the recurrence interval decreases and the subsequent relapse rate increases [2, 5].

Kidney stones are composed of crystals and an organic matrix and are named for their main crystalline constituents. Calcium oxalate (CaOx) alone or in association with calcium phosphate (CaP) is the major component of 75–80% of the kidney stones. Other types of stones include struvite, cystine, uric acid, and ammonium acid urate. [6, 7].

Herbal medicines are a part of the so-called traditional medicine (TM), often termed as “complementary”, “alternative” or “non-conventional” medicine [8]. It refers to local knowledge, belief systems and therapeutic practices that are used in developing countries of Africa, South-East Asia and/or the Western Pacific. Complementary and alternative medicine (CAM) is used when referring to developed countries of Europe, North America and/or Australia [9]. The evolution of different systems of traditional medicine emerged as a result of the traditional knowledge of using herbs for various disorders. The use of herbal medicine in the Indo-Pakistani sub-continent has persisted for centuries and, medicinal plants and their extracts are widely used in the traditional (Unani/Ayurvedic) system of medicine. Complementary and alternative medicine (CAM) is a multibillion-dollars industry globally [10] and has achieved an exponential growth in the last two decades in industrialized countries. Recent research is now showing a remarkable increase in support for, and usage of, therapeutic practices outside mainstream medicine [11]. Many plants have been traditionally used to treat kidney stones and have been shown to be effective [12]. According to the World Health Organization, plants provide an economical and affordable source of drugs for three-quarter of the world population [13] and their therapeutic use is increasing [12]. Within the European Community, annual sales of the herbal medicine are around 7 billion USD, while in the USA, the sale of herbal products has increased from \$200 million in 1988 to > \$3.3 billion in 1997 [14]. In spite of such a high dependency, little scientific research has been carried. This gap between the use of herbal remedies and their scientific basis exists mainly due to the lack of active interactions between the modern health professionals and traditional healers, a lack of modern testing technology, and a shortage of qualified scientists in the field of natural products pharmacology. However, pharmaceutical research centers, universities and even pharmaceutical companies are beginning to fill this gap by bringing teams together and focusing research on phytomedicine [15, 16]. A number of reviews have been published in the past few years on the herbal and traditional medicines for urolithiasis ([8, 17–20], summarizing the results of research articles and commenting on both the potential and challenges. We reviewed the

literature related to the rat models of CaOx nephrolithiasis emphasizing the variety of approaches utilized to prepare and deliver the medicine, methods used to induce the disease, anti-urolithic activities of various treatments and their proposed mechanisms of action. There is a great variation in methods of drug preparation and delivery. Every part of the plant has been ranging from seeds, flowers, fruits, leaves, bark, even whole plants and mixture of various plants have been utilized.

## Methodology

### Literature search

Systematic review of literature was performed according to PRISMA guidelines [21] (Supplementary Figure; PRISMA flow diagram). All publications were retrieved from PubMed in July 2019, with Medical Subject Heading (Mesh) terms; a new and thoroughly revised version of lists of subject headings compiled by National Library of Medicine (NLM) for its bibliographies and cataloguing. The Mesh term “Urolithiasis” (MeshUnique ID: D014545) was used with Boolean operator “AND” and other related Mesh terms “Complementary Therapies/Alternative Medicine; Mesh Unique ID: D000529”, “Plant Extracts; Mesh Unique ID: D010936”, “Traditional Medicine; Mesh Unique ID: D008519 were used to search all the records available up to date, i.e. “Urolithiasis” AND “Complementary Therapies/Complementary Therapies”, “Urolithiasis” AND “Plant Extracts”, “Urolithiasis” AND “Traditional Medicine”.

### Inclusion criteria

In vivo original research articles, PubMed Indexed journals, indexed with Mesh Terms as stated above, studies on rats model of CaOx renal stones.

### Exclusion criteria

In vitro studies, mechanistic in vivo studies without antiurolithic effect, studies on bladder stone disease, review articles, and studies in languages than English.

## Results

A total of 234 articles were extracted using Mesh terms “Urolithiasis” AND “Complementary Therapies” Or “Alternative Medicine” in advance search of PubMed (Supplement Prisma Flow Chart) Based on inclusion and exclusion criteria, a total of 90 articles of animal origin were retrieved. A total of 249 articles were extracted using Mesh

terms “Urolithiasis” AND “Plant Extract” in advance search of PubMed. After selecting animal studies, a total of 142 were retrieved. A total of 52 articles were extracted using Mesh terms “Urolithiasis” AND “Medicine, Traditional” in advance search of PubMed. After selecting animal studies, a total of 20 were retrieved.

After combining all the articles and removing the duplicates, a total of 163 articles were left. After thoroughly screening and reading, another 27 articles were excluded due to unavailability of full text, while another 48 articles were excluded which were either review articles, written in languages other than English, studies involving stone induced by foreign body implantation, or studies focused on mechanisms of urolithiasis risk factors without any investigation of antiurolithic effect. A total of 88 publications were included in this systematic review. Data from all the eligible articles were independently extracted by two researchers and compiled in the form of tables and figures.

Tables 1, 2, 3, 4 show a systematic/chronological compilation of pharmacological studies conducted on aqueous (Table 1), hydroalcoholic (Table 2), alcoholic (Table 3), and other types of extract/formulation (Table 4) of medicinal plants. Each table provides information about the referenced study, year of study, common and scientific name of the plant, part of the plant used, type of extract, crystal inducing agent/model, and antiurolithic activity/mechanism. Reduced crystals deposition, improved renal morphology, reduced oxidative stress, change in urinary pH, decrease in lithogenic factors in urine such as calcium, oxalate, phosphate, increased urinary citrate, improved renal function, altered protein expression, and signs of diuresis were considered as signs of antiurolithic actions of the herbal extracts.

The majority of studies used 0.75–1% ethylene glycol (EG) in drinking alone [22–37] or in combination of ammonium chloride [38–55] (Fig. 1). A small number of studies used other methods to induce CaOx nephrolithiasis. Several used EG along with zinc disk placed in the bladder of the rats for the development of a foreign body stone [56–59]. Others used a combination of gentamicin and calculi producing diet of 5% ammonium oxalate [60, 61], or intraperitoneal injection of sodium oxalate to the Wistar rats [62]. Introduction of CaOx pellet into the bladders of adult male Wistar rats [63], or 3% glycolate diet for 4 weeks [27], or daily intra-abdominal injection of glyoxylate (80 mg/kg) for 12 days [64], or insertion of a series of 15 knots of 5–0 chromic catgut into the urinary bladder [65] were some of the other methods employed. One study employed subcutaneous injection of gentamicin in addition to 5% ammonium oxalate in the rat diet [66]. Other studies involved a single dose of 200 mg glycolic acid given orally [67], implantation of a CaOx seed into the bladder of male Wistar rats [68], 3% glycolic acid mixed with food for 45 days [69], EG and 1 alpha(OH)D3 and 1 alpha-D3-induced

calcium oxalate nephrolithiasis [70], high protein diet [71], and administration of glycollic acid [72].

As illustrated in Figs. 2 and 3 most of the studies utilized aqueous extracts [22–32, 35–40, 64, 67, 73–79], and leaves [29, 30, 33, 35, 38, 40, 44, 49, 66, 80, 81] were the most commonly utilized herbal preparation. Other parts used were fruits [25, 28, 35, 41, 82–86], roots [23, 26, 29, 37, 64, 87–89], seeds [32, 50, 90–95], rhizome [31, 53, 96–98], stem [22, 24, 41], flowers [39, 46], aerial part [23, 42, 45, 47, 76, 99, 100], in addition to other parts such as essential oil of seed [73] or root [73]. Some studies used whole plants [77–79, 101, 102], fronds [43], root bark [52, 103], bark [72], herbal tea [27], rose calyx [75], capitulum [104], pulp [105], herbal medication (Tutukon) [106], spores [107], polyphenolic compounds [108], diosmin: a flavanone glycoside [109], or poly-herbal formulations such as Cystone [110], polyherbal ayurvedic Gokshuradi [55], Mallorcan: a folk herbal extract [111], Wuling-san: a traditional Chinese herbal antilithic formula [112], Choreito [113], Kampou medicines like Takusha [114] and Takusva [70, 115], Zhulingtang (a traditional Chinese herbal formula) [116], Choreito (a herbal preparation), and urajiro-gashi (a herb) [113].

Other methods of extraction included hydroalcoholic [22–25, 27–32, 35, 36, 38–40, 64, 67, 73, 74, 76–79, 93], or alcoholic [29, 33, 47, 49, 60, 80, 83, 88, 90, 95, 99, 102, 105–107, 117], while some studies utilized formulations/constituents like infusions [104], decoctions [61, 69, 85, 118, 119], ultrahigh diluted homeopathic preparation [103], coconut water [120], polysaccharides [100], saponin-rich fraction [84], herbal powder [72, 81, 89, 92, 119], isolated constituents [28], pasteurized juice [91], juice [66, 86] or triterpenoids extracted from plant [121] (Fig. 2).

Calcium oxalate nephrolithiasis in rat models is associated with changes in urinary oxalate, citrate, pH, markers of oxidative stress, production of crystallization modulators and inflammatory molecules, crystalluria and CaOx crystal deposition in the kidneys [54]. All studies did not investigate all the above-mentioned changes associated with nephrolithiasis. But all of them examined crystal deposition in the kidneys and a reduction in crystal deposition was considered a successful outcome of the treatment (Fig. 4). Signs of improved renal structure and functions were reported by most of the studies. Changes in urinary excretion of calcium, oxalate, magnesium, and phosphate were also reported by most studies. Less than 20% of the studies reported changes in urinary pH, citrate, oxidative stress, altered protein expression, and diuresis.

## Discussion

It is important for any drug development to understand the pathogenesis of a disease, in this case, kidney stones. Nephrolithiasis, formation of stones in the kidneys, is a complex,

**Table 1** In vivo studies on the therapeutic effects of aqueous Extracts of Medicinal Plants against CaOx nephrolithiasis

Reference year	Common plant name	Part used	Type of extract	Hyper-oxaluria inducing Agent	Antilithic activities				Improved renal functions	Altered Protein expression	Diuresis
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH			
[38] 2018	Wire weed, knotweed, knotgrass, <i>Polygonum Aviculare</i> L	Leaves	Aqueous extract	EG+AC	+	+					
[35] 2018	Cactus <i>Aliciella heterostyla</i>	Fruit	Aqueous and ethanolic extracts	EG	+	+					
[36] 2017	Stinging nettle <i>Tragia involucrate</i>	Leaves	Aqueous extract and its silver nanoparticles	EG	+	+					
[37] 2017	White poeny root <i>Radix Paeoniae Alba</i>	Dried root without bark	Aqueous extract	EG	+	+				+	
[39] 2017	Ram basak <i>Phlogacanthus thymifolius</i> Hardow (Mabb)	Flowers	Aqueous extract & silver nanoparticles	EG+AC	+	+					
[22] 2017	Cherry <i>Cerasus Avium</i>	Stem	Aqueous extracts	EG	+	+					
[73] 2016	Black Cumin <i>Nigella Sativa</i> L	Essential oil from seed	Hydro distillation	EG+AC	+	+					+

Table 1 (continued)

Reference year	Common plant name	Part used	Type of extract	Hyper-oxaluria inducing Agent	Antiurolithic activities									
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca + +, Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis	
[40] 2015	Common mallow	Leaves	Aqueous extract	EG+AC	+	+								
<i>Maba Neglecta</i> Wallr														
[74] 2013	Sanshishi		Hot water extract		+									
<i>Gardeniae Fructus</i>														
[23] 2012	Parsley	Aerial part and roots	Aqueous extracts	EG	+	+								
<i>Petroselinum sativum</i>														
[24] 2012	Fiery costus or spiral flag	Stem	Aqueous and ethanolic extract and isolated compounds	EG	+	+					+			+
<i>Costus igneus</i>														
[75] 2012	Roselle	Calyx	Aqueous extract	EG+AC	+	+								+
<i>Hibiscus sabdariffa</i> L														
[25] 2012	Red silk-cotton	Fruit	Aqueous and ethanol extracts	EG	+	+					+			
<i>Bombax ceiba</i> L														
[26] 2012	Chaff-Flower	Root	Aqueous extract	EG	+	+								+
<i>Achyranthes aspera</i> Linn														

Table 1 (continued)

Reference year	Common plant name	Part used	Type of extract	Hyper-oxaluria inducing Agent	Antiurolithic activities							
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca + +, Ox, Phosphate)	Improved renal functions	Altered Protein expression
[27] 2011	Roselle	Herbal tea	Aqueous extract	EG	+							+
	<i>Hibiscus sabdariffa</i>											
[27] 2011	Carry Me Seed	Herbal tea	Aqueous extract	3% glycolic acid in diet	+				+			+
	<i>Phyllanthus amarus</i>											
[28] 2011	Bishop's weed	Fruit	Aqueous extract	EG	+				+			
	<i>Ammi visnaga</i> L. And its constituents khellin and visnagin											
[64] 2011	Raspberry	Young roots	Aqueous extract	Glyoxylate (i.p. injections)	+					+		+
	<i>Rubus idaeus</i>											
[29] 2010	Wild Guava (Miswak; Toothbrush Tree)	Leaves	Aqueous and alcoholic extracts	EG	+					+		+
	<i>Salvadora persica</i>											
[30] 2009	Urocalun: compound herbal formulation	Twig leaves	Aqueous extracts of <i>Quercus salicina</i> Blume/ <i>Quercus stenophylla</i> Makino	EG	+					+		

Table 1 (continued)

Reference year	Common plant name	Part used	Type of extract	Hyper-oxaluria inducing Agent	Antiurolithic activities										
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca + +, Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis		
[31] 2009	Bermuda Grass	Rhizome	Aqueous extract	EG	+										
	<i>Cynodon dactylon</i>														
[32] 2007	Common Fenugreek, Greek-Turkey clover,	Seeds	Aqueous extract	EG	+										
	<i>Trigonella foenum-graecum</i> L														
[67], 2007, (122), 1997	Lemongrass		Extract	Glycolic acid	+	+	+	+	+	+	+	+			+
	<i>Cymbopogon schoenanthus</i> (Al-Ethkher)														
[76] 2006	Mountain knotgrass	Aerial parts	Aqueous suspension of dried powdered of aerial parts	EG	+				+	+					
	<i>Aerva lanata</i>														
[77–79] 2004, 2003	Rupture wort	Whole herb	Aqueous extract	EG	+					+					
	<i>Herniaria hirsute</i>														
[93] 2001	Bishop's Weed	Seed	Aqueous extract	Glycolic acid	+					+					+
	<i>Ammi vis-naga</i> (Al-Khillah)														

Urinary lithogenic factors: increased Ca + +, Ox and Phosphate and reduced Mg + + in urine + indicate the presence of activity/mechanisms, EG ethylene glycol, AC ammonium chloride

**Table 2** In vivo studies on therapeutic effect of hydro-alcoholic extracts of medicinal plants against CaOx nephrolithiasis in rats

Reference year	Common name	Part used	Type of extract	Hyperoxaluria inducing agents	Antiurolithic Activities											
					Reduced crystaldeposition	Improved renal architecture	Reduced oxidative stress/antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca++, Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis			
[33] 2017	Fat hen	Leaves	Methanolic and aqueous extracts	EG	+		+				+					
<i>Chenopodium album</i> Linn																
[96] 2017	Velvet leaf	Dried rhizome	Aqueous methanolic extract and dichloromethane (DCM) fraction	EG	+	+										
<i>Bergenia ligulata</i>																
[34] 2017	French plantain	Pseudostem	Aqueous-ethanol extract	EG	+	+					+					
<i>Musa paradisiaca</i>																
[41] 2016	Doqu, Hill Carrot	Fruit	50% aqueous-ethanolic (hydroalcoholic) extract	EG+AC	+	+					+					
<i>Peucedanum grande</i> C. B. Clark																
[101] 2016	Tagulinai	Whole plant	Hydroalcoholic extract	EG	+	+					+					+
<i>Vernonia cinerea</i> Less																
[42] 2015	Coin-leaf	Aerial part	70% aqueous ethanolic	EG+AC	+	+					+					
<i>Desmodium styracifolium</i>																
[94] 2015	Kulattha	Seeds	70% hydroalcoholic extract	EG	+	+					+					
<i>Dolichos biflorus</i>																



Table 2 (continued)

Reference year plant name	Common name	Part used	Type of extract	Hyperoxaluria inducing agents	Antiurolithic Activities									
					Reduced crystaldeposition	Improved renal architecture	Reduced oxidative stress/antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca++, Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis	
[97] 2014 <i>Bergenia ciliata</i>	Hairy Bergenia	Rhizome	Hydro-methanol (30:70) extract	EG	+					+				
[43] 2013 <i>Adiantum capillus veneris</i> Linn	Maidenhair fern	Fronds	Hydro alcoholic extract (aqueous ethanol)	EG + AC		+				+				
[82] 2012 <i>Rosa canina</i> L	Rose Hips / Dogrose	Fruit	Hydroalcoholic extract	EG	+				+					
[24] 2012 <i>Costus igneus</i>	Fiery costus or spiral flag	Stem	Aqueous and ethanolic extract and isolated compounds lupeol and stigmasterol	EG	+					+				+
[50] 2012 <i>Holarrhena antidysenterica</i>	Conessi / Kurchi	Seeds	Hydroalcoholic extract	EG + AC	+					+				+
[44] 2012 <i>Hypericum perforatum</i> L	St. John's-wort	Leaves	Hydroalcoholic extract	EG + AC	+					+				

Table 2 (continued)

Reference year	Common name	Part used	Type of extract	Hyperoxaluria inducing agents	Antiurolithic Activities									
					Reduced crystaldeposition	Improved renal architecture	Reduced oxidative stress/antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca++ , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis	
[45] 2012	In ayurvedic literature as Ikshura, Ikshugandha, and Kokilasha	Arial part	Aqueous-methanolic (80%) extract	EG +AC	+					+				
[25] 2012	Red silk-cotton	Fruit	Aqueous and ethanol extracts	EG	+					+				
[98] 2011	Paashaanbhed	Rhizome	Hydroalcoholic extract	EG	+	+								
[46] 2011	Everlastin, Immortal flower or fadeless flower	Flower	Hydroalcoholic extract (50%)	EG+AC	+	+				+				+
[29] 2010	Wild Guava (Miswak; Toothbrush Tree)	Leaves	Aqueous and alcoholic extracts	EG	+	+								+
[87] 2010	Indian Madder	Root	Hydroalcoholic extract	EG	+	+				+				+
[52] 2010 (105)	Barberry	Root bark	Crude aqueous-methanol extract	EG	+	+								+

Table 2 (continued)

Reference year	Common name	Part used	Type of extract	Hyperoxaluria inducing agents	Antiurolithic Activities								
					Reduced crystaldeposition	Improved renal architecture	Reduced oxidative stress/antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca++ , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis
[53] 2009	Bergenia, Winter	Rhizome	Aqueous-methanolic extract	EG	+	+	+	+	+	+	+		
	<i>Bergenia ligulata</i>												

Urinary lithogenic factors: increased Ca++ , Ox and phosphate and reduced Mg++ in urine  
 + indicate the presence of activity/mechanisms, EG Ethylene Glycol, AC Ammonium Chloride

multifactorial, and multistep process resulting from physicochemical changes in the urinary environment, leading to crystal nucleation, growth aggregation, and retention at specific sites within the kidneys [2, 122, 123]. Interacting urinary ions and a variety of crystallization modulatory macromolecules are involved [124–127]. Most of the idiopathic CaOx stones develop over a foundation of biological apatite, called Randall’s plaque (RP). The plaque starts in the renal papillary interstitium, which grows outward to the papillary surface and becomes exposed to the pelvic urine once surface epithelium/urothelium disintegrates [128]. Some stones, however also form attached to tubular crystal deposits seen plugging the terminal collecting ducts [128, 129]. Thus kidney stones are crystal deposits in the kidneys, but all renal crystalline deposits are not kidney stones.

Several in vitro and in vivo models have been established to explore the pathogenesis of CaOx nephrolithiasis and to develop therapeutic agents and protocols for testing their efficacies [122, 130, 131]. In the in vitro crystallization experiments, calcium oxalate crystal nucleation, growth, and aggregation are investigated in the absence and presence of the crystallization modulators [132, 133]. These in vitro methods give an easy and quick estimate of crystallization modifying activity, preliminary screening for anti-urolithic activity and possible mode(s) of action. However, the biological system and the pathogenesis of urolithiasis is too complex and these in vitro results cannot be safely extrapolated for the therapeutic effect [131]. Therefore, in vivo animal models of CaOx nephrolithiasis to better understand the pathogenesis of nephrolithiasis and investigate the anti-urolithic actions and potential of various drugs have been developed [134].

Experimental nephrolithiasis is produced by the administration of hyperoxaluria inducing agents through diet, drinking water or injection [79, 122, 135]. These in vivo models have a great contribution in understanding of several human pathologies and will remain as a main tool for providing methods and designs to the researcher for the countless biochemical events, physiological processes, and testing of novel pharmaco-therapeutic agents [136]. Investigators have been utilizing these models of hyperoxaluric rats for decades despite obvious differences between rats and human kidneys. The rat kidneys are smaller weighing around 0.75–1.2 g, measuring 1.6 × 1 × 0.9 cm, and are unipapillate, while human kidneys weigh approx.. 170 g, measure 11 × 6 × 2 cm and are multi-papillary, however, despite the gross differences, the cortex–medulla ratio (2:1) of rat’s kidney is similar to human’s [137]. The majority of the studies of herbal use discussed here have utilized the rat model of nephrolithiasis by giving EG in their drinking water alone [33, 34] or with an addition of ammonium chloride [79, 138, 139]. EG, a precursor of oxalic acid, quickly absorbed from the GIT and metabolized to oxalic acid by hepatic enzymes.

Table 3 In vivo studies on therapeutic effect of alcoholic extracts of medicinal plants against CaOx nephrolithiasis in rats

Reference year plant name	Common name	Part used	Type of extract	Hyper-oxaluria inducing agents	Antiurolithic activities								
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca <sup>++</sup> , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis
[105] 2018 <i>Citrullus lanatus</i>	Water melon	Pulp	Ethanolic extract	EG	+	+	+	+	+	+	+	+	+
[33] 2017 <i>Chenopodium album</i> Linn	Fat hen	Leaves	Methanolic and aqueous extracts	EG	+		+			+		+	
[49] 2016 <i>Ipomoea eritocarpa</i>	Tiny Morning Glory	Leaves	Ethanolic extract	EG	+	+				+		+	
[60] 2015 <i>Sarghasum Wightii</i>	Brown algae		Phlorotannin rich extract	5% ammonium oxalate in diet + gentamycin	+	+				+			
[106] 2015 Herbal medicine (Tutukon)	A compound preparation of herbal ingredients: essential oils, flavonoids quercetin, polysaccharides, rosmarinic acid, boldin, flavone glycosides			EG	+								+
[47] 2014 <i>Urtica dioica</i>	Stinging Nettle	Aerial part	Methanol extract	EG+AC	+					+		+	
[107] 2014 <i>Lygodium umja ponicum</i>	Lygodium Spora	Spores	Ethanol extract	EG	+	+	+			+		+	

Table 3 (continued)

Reference year plant name	Common name	Part used	Type of extract	Hyper-oxaluria inducing agents	Antiurolithic activities										
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca <sup>++</sup> , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis		
[83] 2013 <i>Pedalium murex</i> Linn	Bada Gokhru	Fruit	Ethanolic extract	EG	+	+				+					
[95] 2012 <i>Hordeum vulgare</i>	Barley	Seeds	Ethanolic extract	EG	+	+	+		+						+
[102] 2012 <i>Leea macrophylla</i>	Hastikar-napalsa	Whole plant	Ethanolic extract	EG	+	+				+					
[117] 2012 <i>Asparagus racemosus</i>	Shatavari / shatamuli		Ethanolic extract	EG+AC	+	+				+					
[88] 2011 <i>Urtica dentata</i> hand; a traditional Chinese herbal medicine,		Root	N-butanol extract (NBE)	EG+AC	+	+				+					+
[29] 2010 <i>Salvadora persica</i>	Wild Guava (Miswak; Toothbrush Tree)	Leaves	Aqueous and alcoholic extracts	EG	+	+				+					

Table 3 (continued)

Reference year plant name	Common name	Part used	Type of extract	Hyper-oxaluria inducing agents	Antiurolithic activities										
					Reduced crystals deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca ++, Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis		
[99] 2010	Algerian tea	Aerial part	Butanolic extract	EG	+	+				+	+				
	<i>Paronychia argentea</i>														
[90] 2007	Black cummin	Seeds	Ethanollic extract	EG	+					+					
	<i>Nigella sativa</i> L														
[80] 2005	Shatavari / Shata-	Leaves	Ethanollic extract	EG	+	+				+	+				
	<i>Asparagus racemosus</i> Willd	multi													

Urinary lithogenic factors: increased Ca ++, Ox and phosphate and reduced Mg++ in urine  
+ indicate the presence of activity/mechanisms, EG ethylene glycol, AC ammonium chloride

**Table 4** In vivo studies on therapeutic effect of medicinal plant formulations against CaOx nephrolithiasis

Reference year	Common name	Part used	Type of extract/formulation	Hyperoxaluria inducing agents	Antiurolithic activities								
					Reduced crystal deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca <sup>++</sup> , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis
[108] 2017	The red-bark oak	Polyphenolic compounds: (-)-epicatechin, procyanidin, and procyanidin		EG	+			+					+
<i>Quercus gilva</i> Blume													
[109] 2016	Iberian German-der	Diosmin: a flavanone glycoside		EG+AC	+	+			+			+	
<i>Teucrium gnaphalodes</i> L'Her													
[104] 2016	Immortal flower	Capitulum	Infusions	Sodium oxalate	+				+			+	+
<i>Helichrysum stoechas</i> (L.) and <i>Helichrysum graveolens</i>													
[118] 2016	No-Kanzo	NA	Decoction	EG	+				+			+	+
<i>Glechoma longituba</i>													
[106] 2015	Herbal medication (Tutukon)	A compound preparation of herbal ingredients: Essential oils, flavonoids quercetin, polysaccharides, rosmarinic acid, boldin, flavone glycosides		EG	+								+
[103] 2013	Barberry	Root bark	Ultrahigh diluted homeopathic preparation	EG	+						+		+
<i>Berberis Vulgaris</i>													
[120] 2013	Coconut	Coconut water		EG	+	+						+	+
<i>Cocos nucifera</i> L.													

Table 4 (continued)

Reference year	Common name	Part used	Type of extract/formulation	Hyperoxaluria inducing agents	Antiurolithic activities								
					Reduced crystal deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca <sup>++</sup> , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis
[110] 2013	Syrup preparation of extracts of Tribulus terrestris L., Boerhavia diffusa L., Saxifraga ligulata Murray, Cyperus rotundus L., Asparagus racemosus Willd., Dolichos biflorus L., Vetiveria zizanioides L., Cureuma zedoaria Roxb., Saindhava Suvarchika, Yavakshara, Narasara			EG	+	+	+	+	+	+	+	+	+
[55] 2013	Polyherbal ayurvedic formulation			EG + AC	+		+						+
<i>Gokshuradi Yog (GY) i</i>													
[100] 2012	<i>Kumis kacting</i>	Aerial part	Polysaccharides and ethyl acetate fraction	EG + AC	+					+		+	+
<i>Orithosiphon stamineus</i> Benth													
[84] 2012	Yellow Berried Nightshade	Fruit	Saponin-rich fraction	EG	+					+		+	+
<i>Solanum xanthocarpum</i> Schrad & Wendl													
[61] 2012	Coin-leaf desmodium	Not given	Decoction	5% ammonium oxalate (AmOX)	+					+		+	+
<i>Desmodium styracifolium</i>													
[61] 2012	Shearer's pyrrrosia leaf	Not given	Decoction	EG	+					+		+	+
<i>Pyrrrosia petiolaris</i>													
[119] 2012	Safflower		Herbal powder	EG	+								
<i>Flos carthami</i>													



Table 4 (continued)

Reference year	Common name	Part used	Type of extract/formulation	Hyperoxaluria inducing agents	Antiurolithic activities									
					Reduced crystal deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca <sup>++</sup> , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis	
[28] 2011	Bishop's weed		Isolated constituents	EG	+									
	<i>Ammi visnaga</i> L. isolated constituents													
	khellin and visnagin													
[85] 2010	Tehran pine	Fruit	Decoction	EG	+						+			+
	<i>Pinus elliatica</i> medw:													
[81] 2010	Java tea	Fresh leaves	Finely powdered		+									
	<i>Orthosiphon grandiflorum</i>													
[116] 2009	Composed of 5 dried herbs: Polyporus umbellatus (Pers.) Fries, Portia cocos (Schw.) Wolf, alismatis rhizoma, talcum and colla corii asini			EG	+									
	Zhulingtang (a traditional Chinese herbal formula)													
[91] 2009	Pomegranate	Seeds	Pasteurized juice	EG	+									+
	<i>Punica granatum</i>													
[111] 2009	Contains fluid extracts of <i>Aretotaphylos</i>			EG	+									
	Folk herbal extract; Mallorcan													
	<i>iva-ursi</i> L., <i>Zea mays</i> L. and <i>Ricinus zanzibariensis</i> L. tincture of <i>Sabal serrulata</i> L., mother tincture of <i>Agathosma betulina</i> L., glycerin, and anis essence													


Table 4 (continued)

Reference year	Common name	Part used	Type of extract/formulation	Hyperoxaluria inducing agents	Antiurolithic activities								
					Reduced crystal deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca <sup>++</sup> , Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis
[112] 2008	Composed of five dried herbs: <i>Alisma orientalis</i> (Sam.), <i>Juzep.</i> , <i>Polyporus umbellatus</i> (Pers) Fries, <i>Atractylodes macrocephala</i> Koidez, <i>Poria cocos</i> (Schw.) Wolf, and <i>Cin-namomum cassia</i> Presl				+	+							
[66] 2008	Corkwood tree;	Leaves	Juice	5% ammonium oxalate in diet + gentamycin	+		+				+		
<i>Sesbania grandiflora</i>	Hummingbird tree;					+							
[86] 2007	Lemon	Fruit	Juice	EG	+						+		
<i>Citrus limon</i>													
[69] 2002	Carmona viminea, /Ehretia viminea, /Rhabdia viminea		Decoction	3% glycolic acid in diet						+			
<i>Rotula aquatic</i> lour													
[89] 2002	Ink berry	Root	Powdered	EG						+			
<i>Cyclea peltata</i> Lam													
[114] 1999	Takusha,; a kampo medicine		A kampo medicine + vit. D <sub>3</sub>	EG	+								+


Table 4 (continued)

Reference year	Common name	Part used	Type of extract/formulation	Hyperoxaluria inducing agents	Antiurolithic activities								
					Reduced crystal deposition	Improved renal architecture	Reduced oxidative stress/mediated antioxidant effect	↑ urine pH	↑ urine Citrate	↓ lithogenic factors in urine (Ca + +, Ox, Phosphate)	Improved renal functions	Altered Protein expression	Diuresis
[115, 70] 1995, 2016	Takuya (Kampou medicine)		Mixture of 16 plant extracts	EG + 1α(OH)D <sub>3</sub>	+	+							+
[121] 1993	Coin-leaf desmodium		Triterpenoid extracted from the plant	EG + 1α(OH)D <sub>3</sub>	+						+		+
[72] 1990	Three leaved caper	Bark	Decoction	Glycolic acid	+						+		
[92] 1989	Fenugreek	Seed	Powdered seeds	3% glycolic acid diet	+								
[113] 1986	Choreito (a herbal preparation), and urajirogashi (a herb)			3% glycolic acid diet	+						+		+

Urinary lithogenic factors: increased Ca + +, Ox and phosphate and reduced Mg + + in urine + indicate the presence of activity/mechanisms, EG = ethylene glycol, AC = ammonium chloride




**Fig. 1** Number of studies based on the methods used for crystals induction



**Fig. 2** Number of studies based on the type of solvent used


EG mostly affects the kidneys with considerable variability in sensitivity across the strains, species, and sexes. Rats are more sensitive than mice and male rats are more sensitive than females. EG (0.75–1%) alone gives variable results of CaOx deposition [140]. To achieve a uniformly high rate of renal crystal deposition and reducing the time required for crystal deposition, a pH reducing, hypercalciuric or nephrotoxic protocol such as ammonium chloride (AC) [140, 141], vitamin D<sub>3</sub> [121], gentamicin [142] or a magnesium-deficient diet has been used in combination with EG. However, treatment with AC 1% or more cannot be extended beyond 4–5 days as rats become sick, lose body weight and drink less water [140]. Hydroxy-L-proline (HLP), a physiologic precursor of oxalate is also used for induction of hyperoxaluria in the rats by oral administration or by intraperitoneal injection [54, 143]. Other hyperoxaluric rat models



**Fig. 3** Number of studies based on the part of the plant used

are produced by inbreeding of hyperoxaluric progeny [144, 145], the administration of sodium oxalate [146], or glycolic acid [147]. In addition, several other models of nephrolithiasis have been developed such as transgenic mouse with selective knockout (KO) of osteopontin (OPN) [148] and Tamm–Horsefall protein (THP) [149], oxalate, sodium phosphate [150], and cysteine transporter [151]. KO mouse model and fly model of CaOx crystals have also been developed. Despite the genomic advantages of the mice model, its overall accuracy and consistency in relation to human kidney stone disease remains controversial among researchers [152]. However, the hyperoxaluric rat model of nephrolithiasis represents a well-established and relatively economic model for the study of urolithiasis [134]. When EG is given at a concentration of 0.75% or above in drinking water, rats developed hyperoxaluria, leading to crystalluria and CaOx crystal deposition in kidney's tubules [122]. Frequency of crystal deposition in kidney range from 80 to 100% of the kidney's area, depending upon the co-administered drug [121, 153] and it takes about 1–3 weeks to develop nephrolithiasis. The prominent features of hyperoxaluria-induced nephrolithiasis include development of oxidative stress in the kidneys, high water intake and polyuria, decreased urinary Ca<sup>++</sup>, Mg<sup>++</sup>, and citrate contents, lower urinary pH, increased phosphate excretion, renal hypertrophy, CaOx crystalluria, and loss of body weight [54, 79, 121]. Other signs of renal damage are increased urinary protein loss, lower creatinine clearance, and raised serum creatinine and blood urea nitrogen (BUN) [54, 154]. All rats, as well as other animal models of hyperoxaluria such as *Drosophila* [155, 156] and pig [157, 158], do not produce kidney stones similar to idiopathic CaOx stones of human. They produce intratubular deposits of CaOx crystals.

**Fig. 4** Number of studies based on the mechanism of antiurolithic activity




Both animal model and tissue culture studies have shown that high oxalate and CaOx as well as CaP crystals cause overproduction of reactive oxygen species (ROS) by the renal epithelial cells leading to renal injury [159, 160]. Signs of oxidative stress have also been reported from clinical studies [159, 161]. Reactive oxygen species also regulate the production of various crystallization modulators which are known to inhibit crystal nucleation, growth, and aggregation [162]. These crystallization modulators also participate in the cellular inflammatory cascade. In addition, the ROS may stimulate osteogenic changes in the renal epithelial [163], and/or vascular endothelial cells. Antioxidants are shown to reduce hyperoxaluria and crystal-associated injury [164]. Herbal treatments of hyperoxaluric rats appear to reduce the oxidative stress, thereby reducing renal epithelial injury, membrane-associated crystal nucleation, and crystal deposition within the renal tubules and kidneys.

A significant majority of studies reviewed here utilized the most well-recognized model of experimental CaOx nephrolithiasis, administration of ethylene glycol through diet. Eight different parts of the plants, including flowers, seeds, fruits, leaves, stems, roots, rhizomes, were used to prepare the herbal treatments. Leaves were the most common ingredient. Aqueous, alcoholic, and hydro-alcoholic solvents were employed to prepare the treatments. Common indicators of nephrolithiasis, such as renal CaOx crystal deposits, markers of oxidative stress, urinary calcium, citrate, oxalate, phosphate, and pH, in addition to improved renal structure and functions were assessed to determine the

efficacy of herbal administration. Unfortunately, all studies did not investigate all of these aspects of nephrolithiasis. However, all the treatments resulted in reduction of CaOx crystal deposition in the kidneys. Majority of studies showed an improvement in both the structure and function of the kidneys following herbal treatments. Studies that determined oxidative stress found that the herbal treatments had antioxidant properties.

Based upon the available data, we can visualize the following sequence of events when hyperoxaluric rats are treated with the diverse herbal preparations. Under normal circumstances, renal epithelial cells produce sufficient ROS to regulate various metabolic processes including inhibition of crystallization by the production of needed macromolecular inhibitors. Crystals, if formed due to the increased intake of calcium and oxalate and the decreased water in the urine, stay small and un-aggregated. Cell membranes are intact and do not promote crystal adherence thereby reducing chances of their retention within the tubules. Crystals, if any, move freely with the urine and discharged during urination (Fig. 5a). The administration of hyperoxaluric agents such as EG alone or in combination with other agents, as discussed above, leads to the production of abnormal urine with high oxalate, low citrate and in the case with vitamin D, increased calcium. Epithelial cells respond by producing access ROS. Cells are injured and respond aberrantly, producing inactive molecular inhibitors or macromolecules that promote crystal nucleation instead of reducing it. Cell membranes promote crystal nucleation and aggregation even



**Fig. 5** Diagrammatic representation of crystallization within the kidneys. The (A) side represents normal urinary conditions. Occasional changes in the urinary calcium (Ca), oxalate (Ox), citrate (Cit), conducive to crystallization lead to the production of reactive oxygen species (ROS) sufficient to generate crystallization inhibitors. Small crystals are formed which are urinated out. The (B) side denotes abnormal and lithogenic urinary conditions. Persistently high Ca and/or Ox, and low Cit causes overproduction of ROS, injuring the renal

tubular epithelium. Cells die, release membrane vesicles promoting crystal nucleation and aggregation. Production of active inhibitors is affected thereby crystals grow unimpeded. Herbal therapies appear to act either on the production of ROS or as their neutralizers. These actions will reduce cell injury and influence the production of active/normal macromolecular inhibitors resulting in reduced crystallization, the formation of small un-aggregated crystals which should easily pass during urination

under lower supersaturation promoting crystal deposition within the tubules. Herbal preparations contain compounds which diminish the production of ROS or/and have antioxidants that neutralize the ROS, leading to a reduction in cell injury and direction towards normalization. As a result, there is a reduction in crystal deposition in the kidneys as has been reported by all the studies undertaken to date (Fig. 5b).

## Conclusions and future direction

Idiopathic CaOx stones form by the deposition and growth of CaOx crystals on Randall's plaques or the Randall's plugs. Plaques are subepithelial deposits of CaP on renal papillae, originating deep inside the medullary/papillary interstitium. We do not yet fully understand the pathogenesis of plaques, which may involve both tubular and vascular inflammation. Plugs are crystal deposits within the terminal collecting ducts

and form as the result of urinary supersaturation and crystal attachment to injured renal tubular epithelium. Most of the plugs are also made of CaP. Reactive oxygen species are likely involved in both the plaque and plug formation because they play a significant role in the production of crystallization modulators, tubular epithelial injury as well as inflammation. Tubular injury produces cellular debris that can promote heterogeneous nucleation of CaP and also provides sites for their adherence and retention within the tubules. Crystallization modulators affect crystal formation by promoting or inhibiting their formation and growth. Animal model studies show that herbal treatments lead to the production of antioxidants, which may be responsible for their positive role in stopping crystal formation/deposition in the animal kidneys and may reduce stone recurrence when given to stone patients.

Where do the recurrent stones form? Do the new stones form on the remnant of the plaque or plug left after stone has passed? Or do they form on the new plaques and new plugs?

Whatever the case, herbal treatment with antioxidant properties can decrease stone recurrence by reducing the crystallization, which shall reduce crystal deposition on the plaques and plugs. In addition, the treatments may reduce crystal formation and deposition in the terminal collecting ducts and the formation of new plugs by reducing epithelial injury. It is unclear whether herbal treatments would have any effect on the formation and deposition of CaP in the renal interstitium and the initiation of the Randall's plaque. It is however possible that herbal treatment stops disintegration of the urothelium and exposure of the sub-urothelial CaP deposits on the papillary surface to the pelvic urine, thereby lessening the possibility of a new stone development.

Great progress has been made in developing and understanding of the mode of action of herbal extracts/preparations as a therapy for stone recurrence. But the range of methodologies used for inducing nephrolithiasis, and in preparing and delivering the extracts does not allow for the comparison between various treatments. In addition, many studies do not consider all aspects of nephrolithiasis. There is also a dearth of knowledge about the bioactive components of various herbal preparations, and their safety profile. What is the effect of extraction method on the bioactive compounds, their quality and quantity? Many of the herbal/alternative medicines are shown to be injurious to the kidneys [19, 20]. Future studies are needed to determine the active compounds present in the herbal preparations and whether those compounds reach the kidneys and urine, and are nontoxic to the kidneys. Researchers should agree upon a panel of features to be investigated to determine the efficacy of a treatment. The herbal treatment should induce changes in the urinary environment that reduce supersaturation, inhibit crystallization, and eventual crystal deposition in the kidneys. It should have antioxidant properties and be able to reduce the production of reactive oxygen species. It should be nontoxic and improve renal structure and functions.

## Compliance with ethical standards

**Conflict of interest** All authors declare no conflict of interest.

**Ethical approval** The article does not contain any studies with human or animal subjects.

## References

- Lopez M, Hoppe B (2008) History, epidemiology and regional diversities of urolithiasis. *Pediatr Nephrol*
- Pak CY (1998) Kidney stones. *Lancet* 351(9118):1797–1801
- Brikowski TH, Lotan Y, Pearle MS (2008) Climate-related increase in the prevalence of urolithiasis in the United States. *Proc Natl Acad Sci U S A* 105(28):9841–9846. <https://doi.org/10.1073/pnas.0709652105>
- Pedro RN, Aslam AU, Bello JO, Bhatti KH, Philipraj J, Sissoko I, Vasconcellos GS, Trinchieri A, Buchholz N (2020) Nutrients, vitamins, probiotics and herbal products: an update of their role in urolithogenesis. *Urolithiasis*:1–17
- Moe OW, Huang CL (2006) Hypercalciuria from acid load: renal mechanisms. *J Nephrol* 19(Suppl 9):S53–61
- Lemann J Jr (1993) Composition of the diet and calcium kidney stones. *N Engl J Med* 328(12):880–882. <https://doi.org/10.1056/NEJM199303253281212>
- Evan AP (2010) Physiopathology and etiology of stone formation in the kidney and the urinary tract. *Pediatr Nephrol* 25(5):831–841. <https://doi.org/10.1007/s00467-009-1116-y>
- Butterweck V, Khan SR (2009) Herbal medicines in the management of urolithiasis: alternative or complementary? *Planta Med* 75(10):1095–1103. <https://doi.org/10.1055/s-0029-1185719>
- World Health O (2002) WHO Traditional Medicine Strategy 2002–2005. World Health Organization Geneva, Switzerland
- Eastwood HL (2000) Complementary therapies: the appeal to general practitioners. *Med J Aust* 173(2):95–98
- Tovey PA, Broom AF, Chatwin J, Ahmad S, Hafeez M (2005) Use of traditional, complementary and allopathic medicines in Pakistan by cancer patients. *Rural Remote Health* 5(4):447
- Hollenberg D, Zakus D, Cook T, Xu XW (2008) Re-positioning the role of traditional, complementary and alternative medicine as essential health knowledge in global health: do they still have a role to play? *World Health Popul* 10(4):62–75
- Gilani AH, Rahman AU (2005) Trends in ethnopharmacology. *J Ethnopharmacol* 100(1–2):43–49. <https://doi.org/10.1016/j.jep.2005.06.001>
- Mahady GB (2001) Global harmonization of herbal health claims. *J Nutr* 131(3s):1120S–1123S
- Bashir S, Memon R, Gilani AH (2011) Antispasmodic and Antidiarrheal Activities of *Valeriana hardwickii* Wall. Rhizome Are Putatively Mediated through Calcium Channel Blockade. Evidence-based complementary and alternative medicine: eCAM 2011:304960. doi:<https://doi.org/10.1155/2011/304960>
- Gilani A, Molla N, Rahman AU, Shah BH (1992) Phytotherapy - the role of natural products in modern medicine. *J Pharm Med* 2:111–118
- Kasote DM, Jagtap SD, Thapa D, Khyade MS, Russell WR (2017) Herbal remedies for urinary stones used in India and China: A review. *J Ethnopharmacol* 203:55–68. <https://doi.org/10.1016/j.jep.2017.03.038>
- Miyaoka R, Monga M (2009) Use of traditional Chinese medicine in the management of urinary stone disease. *Int Braz J Urol* 35(4):396–405. <https://doi.org/10.1590/s1677-55382009000400002>
- Colson CR, De Broe ME (2005) Kidney injury from alternative medicines. *Advances in chronic kidney disease* 12(3):261–275. <https://doi.org/10.1016/j.ackd.2005.03.006>
- Brown AC (2017) Kidney toxicity related to herbs and dietary supplements: Online table of case reports. Part 3 of 5 series. *Food Chem Toxicol* 107 (Pt A):502–519. doi:<https://doi.org/10.1016/j.fct.2016.07.024>
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 62(10):e1–e34
- Azaryan E, Malekaneh M, Shemshadi Nejad M, Haghghi F (2017) Therapeutic Effects of Aqueous Extracts of *Cerasus Avium* Stem on Ethylene Glycol- Induced Kidney Calculi in Rats. *Urol J* 14(4):4024–4029

23. Saeidi J, Bozorgi H, Zendehtdel A, Mehrzad J (2012) Therapeutic effects of aqueous extracts of *Petroselinum sativum* on ethylene glycol-induced kidney calculi in rats. *Urol J* 9(1):361–366
24. Manjula K, Rajendran K, Eevera T, Kumaran S (2012) Effect of *Costus igneus* stem extract on calcium oxalate urolithiasis in albino rats. *Urol Res* 40(5):499–510. <https://doi.org/10.1007/s00240-012-0462-6>
25. Gadge NB, Jalalpure SS (2012) Curative treatment with extracts of *Bombax ceiba* fruit reduces risk of calcium oxalate urolithiasis in rats. *Pharm Biol* 50(3):310–317. <https://doi.org/10.3109/13880209.2011.604332>
26. Aggarwal A, Singla SK, Gandhi M, Tandon C (2012) Preventive and curative effects of *Achyranthes aspera* Linn. extract in experimentally induced nephrolithiasis. *Indian J Exp Biol* 50(3):201–208
27. Woottisin S, Hossain RZ, Yachantha C, Sriboonlue P, Ogawa Y, Saito S (2011) Effects of *Orthosiphon grandiflorus*, *Hibiscus sabdariffa* and *Phyllanthus amarus* extracts on risk factors for urinary calcium oxalate stones in rats. *J Urol* 185(1):323–328. <https://doi.org/10.1016/j.juro.2010.09.003>
28. Vanachayangkul P, Chow N, Khan SR, Butterweck V (2011) Prevention of renal crystal deposition by an extract of *Ammi visnaga* L. and its constituents khellin and visnagin in hyperoxaluric rats. *Urological research* 39(3):189–195. doi:<https://doi.org/10.1007/s00240-010-0333-y>
29. Geetha K, Manavalan R, Venkappayya D (2010) Control of urinary risk factors of stone formation by *Salvadora persica* in experimental hyperoxaluria. *Methods Find Exp Clin Pharmacol* 32(9):623–629. <https://doi.org/10.1358/mf.2010.32.9.1549114>
30. Moriyama MT, Suga K, Miyazawa K, Tanaka T, Higashioka M, Noda K, Oka M, Tanaka M, Suzuki K (2009) Inhibitions of urinary oxidative stress and renal calcium level by an extract of *Quercus salicina* Blume/*Quercus stenophylla* Makino in a rat calcium oxalate urolithiasis model. *Int J Urol* 16(4):397–401. <https://doi.org/10.1111/j.1442-2042.2009.02268.x>
31. Atmani F, Sadki C, Aziz M, Mimouni M, Hacht B (2009) *Cynodon dactylon* extract as a preventive and curative agent in experimentally induced nephrolithiasis. *Urol Res* 37(2):75–82. <https://doi.org/10.1007/s00240-009-0174-8>
32. Laroubi A, Touhami M, Farouk L, Zrara I, Aboufatima R, Benharref A, Chait A (2007) Prophylaxis effect of *Trigonella foenum graecum* L. seeds on renal stone formation in rats. *Phytother Res* 21(10):921–925. doi:<https://doi.org/10.1002/ptr.2190>
33. Sikarwar I, Dey YN, Wanjari MM, Sharma A, Gaidhani SN, Jadhav AD (2017) *Chenopodium album* Linn. leaves prevent ethylene glycol-induced urolithiasis in rats. *J Ethnopharmacol* 195:275–282. <https://doi.org/10.1016/j.jep.2016.11.031>
34. Panigrahi PN, Dey S, Sahoo M, Dan A (2017) Antiurolithiatic and antioxidant efficacy of *Musa paradisiaca* pseudostem on ethylene glycol-induced nephrolithiasis in rat. *Indian J Pharmacol* 49(1):77–83. <https://doi.org/10.4103/0253-7613.201026>
35. Partovi N, Ebadzadeh MR, Fatemi SJ, Khaksari M (2018) Effect of fruit extract on renal stone formation and kidney injury in rats. *Nat Prod Res* 32(10):1180–1183. <https://doi.org/10.1080/14786419.2017.1320790>
36. Velu V, Das M, Raj NA, Dua K, Malipeddi H (2017) Evaluation of in vitro and in vivo anti-urolithiatic activity of silver nanoparticles containing aqueous leaf extract of *Tragia involucrata*. *Drug Deliv Transl Res* 7(3):439–449. <https://doi.org/10.1007/s13346-017-0363-x>
37. Li X, Wang W, Su Y, Yue Z, Bao J (2017) Inhibitory effect of an aqueous extract of *Radix Paeoniae Alba* on calcium oxalate nephrolithiasis in a rat model. *Ren Fail* 39(1):120–129. <https://doi.org/10.1080/0886022X.2016.1254658>
38. Saremi J, Kargar Jahromi H, Pourahmadi M (2018) Effect of *Polygonum Aviculare* L. on Nephrolithiasis Induced by Ethylene Glycol and Ammonium Chloride in Rats. *Urol J* 15(3):79–82. doi:<https://doi.org/10.22037/uj.v0i0.3815>
39. Das P, Kumar K, Nambiraj A, Rajan R, Awasthi R, Dua K, M H, (2017) Potential therapeutic activity of *Phlogacanthus thyr-siformis* Hardow (Mabb) flower extract and its biofabricated silver nanoparticles against chemically induced urolithiasis in male Wistar rats. *Int J Biol Macromol* 103:621–629. <https://doi.org/10.1016/j.ijbiomac.2017.05.096>
40. Saremi J, Kargar-Jahroomi H, Poorahmadi M (2015) Effect of *Malva Neglecta* Wallr on Ethylene Glycol Induced Kidney Stones. *Urol J* 12(6):2387–2390
41. Kumar BN, Wadud A, Jahan N, Sofi G, Bano H, Makbul SA, Husain S (2016) Antilithiatic effect of *Peucedanum grande* C. B. Clarke in chemically induced urolithiasis in rats. *J Ethnopharmacol* 194:1122–1129. <https://doi.org/10.1016/j.jep.2016.10.081>
42. Xiang S, Zhou J, Li J, Wang Q, Zhang Q, Zhao Z, Zhang L, Chen Z, Wang S (2015) Antilithic effects of extracts from different polarity fractions of *Desmodium styracifolium* on experimentally induced urolithiasis in rats. *Urolithiasis* 43(5):433–439. <https://doi.org/10.1007/s00240-015-0795-z>
43. Ahmed A, Wadud A, Jahan N, Bilal A, Hajera S (2013) Efficacy of *Adiantum capillus veneris* Linn in chemically induced urolithiasis in rats. *J Ethnopharmacol* 146(1):411–416. <https://doi.org/10.1016/j.jep.2013.01.011>
44. Khalili M, Jalali MR, Mirzaei-Azandaryani M (2012) Effect of hydroalcoholic extract of *Hypericum perforatum* L. leaves on ethylene glycol-induced kidney calculi in rats. *Urol J* 9(2):472–479
45. Ingale KG, Thakurdesai PA, Vyawahare NS (2012) Effect of *Hygrophila spinosa* in ethylene glycol induced nephrolithiasis in rats. *Indian J Pharmacol* 44(5):639–642. <https://doi.org/10.4103/0253-7613.100402>
46. Bayir Y, Halici Z, Keles MS, Colak S, Cakir A, Kaya Y, Akcay F (2011) *Helichrysum plicatum* DC. subsp. *plicatum* extract as a preventive agent in experimentally induced urolithiasis model. *J Ethnopharmacol* 138(2):408–414. doi:<https://doi.org/10.1016/j.jep.2011.09.026>
47. Zhang H, Li N, Li K, Li P (2014) Protective effect of *Urtica dioica* methanol extract against experimentally induced urinary calculi in rats. *Mol Med Rep* 10(6):3157–3162. <https://doi.org/10.3892/mmr.2014.2610>
48. Yousefi Ghale-Salimi M, Eidi M, Ghaemi N, Khavari-Nejad RA (2018) Antiurolithiatic effect of the taraxasterol on ethylene glycol induced kidney calculi in male rats. *Urolithiasis* 46(5):419–428. <https://doi.org/10.1007/s00240-017-1023-9>
49. Das M, Malipeddi H (2016) Antiurolithiatic activity of ethanol leaf extract of *Ipomoea eriocarpa* against ethylene glycol-induced urolithiasis in male Wistar rats. *Indian J Pharmacol* 48(3):270–274. <https://doi.org/10.4103/0253-7613.182886>
50. Khan A, Khan SR, Gilani AH (2012) Studies on the in vitro and in vivo antiurolithic activity of *Holarrhena antidysenterica*. *Urol Res* 40(6):671–681. <https://doi.org/10.1007/s00240-012-0483-1>
51. Khan A, Bashir S, Khan SR, Gilani AH (2011) Antiurolithic activity of *Origanum vulgare* is mediated through multiple pathways. *BMC Complement Altern Med* 11:96. <https://doi.org/10.1186/1472-6882-11-96>
52. Bashir S, Gilani AH, Siddiqui AA, Pervez S, Khan SR, Sarfaraz NJ, Shah AJ (2010) *Berberis vulgaris* root bark extract prevents hyperoxaluria induced urolithiasis in rats. *Phytother Res* 24(8):1250–1255. <https://doi.org/10.1002/ptr.3196>
53. Bashir S, Gilani AH (2009) Antiurolithic effect of *Bergenia ligulata* rhizome: an explanation of the underlying mechanisms. *J Ethnopharmacol* 122(1):106–116. <https://doi.org/10.1016/j.jep.2008.12.004>



54. Khan SR, Glenton PA, Byer KJ (2006) Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. *Kidney Int* 70(5):914–923. <https://doi.org/10.1038/sj.ki.5001699>
55. Shirfule AL, Racharla V, Qadri S, Khandare AL (2013) Exploring antiurolithic effects of gokshuradi polyherbal ayurvedic formulation in ethylene-glycol-induced urolithic rats. Evidence-Based Complementary and Alternative Medicine 2013
56. Yuruk E, Tuken M, Sahin C, Kaptanagasi AO, Basak K, Aykan S, Muslumanoglu AY, Sarica K (2016) The protective effects of an herbal agent tutukon on ethylene glycol and zinc disk induced urolithiasis model in a rat model. *Urolithiasis* 44(6):501–507. <https://doi.org/10.1007/s00240-016-0889-2>
57. Vargas Solis R, Perez Gutierrez RM (2002) Diuretic and urolithiatic activities of the aqueous extract of the fruit of *Randia echinocarpa* on rats. *J Ethnopharmacol* 83(1–2):145–147
58. Vargas R, Perez RM, Perez S, Zavala MA, Perez C (1999) Antiurolithiatic activity of *Raphanus sativus* aqueous extract on rats. *J Ethnopharmacol* 68(1–3):335–338
59. Araújo Viel T, Diogo Domingos C, da Silva Monteiro AP, Rígio Lima-Landman MT, Lapa AJ, Souccar C (1999) Evaluation of the antiurolithiatic activity of the extract of *Costus spiralis* Roscoe in rats. *J Ethnopharmacol* 66(2):193–198
60. Sujatha D, Singh K, Vohra M, Kumar KV, Sunitha S (2015) Antilithiatic Activity of phlorotannin rich extract of *Sarghasum wightii* on Calcium Oxalate Urolithiasis - In Vitro and In Vivo Evaluation. *Int Braz J Urol* 41(3):511–520. <https://doi.org/10.1590/S1677-5538.IBJU.2014.0357>
61. Mi J, Duan J, Zhang J, Lu J, Wang H, Wang Z (2012) Evaluation of antiurolithic effect and the possible mechanisms of *Desmodium styracifolium* and *Pyrrrosiae petiolosa* in rats. *Urol Res* 40(2):151–161. <https://doi.org/10.1007/s00240-011-0401-y>
62. Orhan N, Onaran M, Sen I, Isik Gonul I, Aslan M (2015) Preventive treatment of calcium oxalate crystal deposition with immortal flowers. *J Ethnopharmacol* 163:60–67. <https://doi.org/10.1016/j.jep.2015.01.009>
63. Brancalion AP, Oliveira RB, Sousa JP, Groppo M, Berretta AA, Barros ME, Boim MA, Bastos JK (2012) Effect of hydroalcoholic extract from *Copaifera langsdorffii* leaves on urolithiasis induced in rats. *Urol Res* 40(5):475–481. <https://doi.org/10.1007/s00240-011-0453-z>
64. Ghalayini IF, Al-Ghazo MA, Harfeil MN (2011) Prophylaxis and therapeutic effects of raspberry (*Rubus idaeus*) on renal stone formation in Balb/c mice. *Int Braz J Urol* 37(2):259–266; discussion 267. doi:<https://doi.org/10.1590/s1677-55382011000200013>
65. Portilla-de Buen E, Ramos L, Aguilar A, Ramos A, Garcia-Martinez D, Cardenas A, Rodriguez-Reynoso S, Leal C (2008) [Larrea tridentata. Effect on a non-metabolic model of urolithiasis in rats]. *Rev Med Inst Mex Seguro Soc* 46(5):519–522
66. Doddola S, Pasupulati H, Koganti B, Prasad KV (2008) Evaluation of *Sesbania grandiflora* for antiurolithiatic and antioxidant properties. *J Nat Med* 62(3):300–307. <https://doi.org/10.1007/s11418-008-0235-2>
67. Al-Ghamdi SS, Al-Ghamdi AA, Shammah AA (2007) Inhibition of calcium oxalate nephrotoxicity with *Cymbopogon schoenanthus* (Al-Ethkher). *Drug Metab Lett* 1(4):241–244. <https://doi.org/10.2174/187231207783221420>
68. Barros ME, Lima R, Mercuri LP, Matos JR, Schor N, Boim MA (2006) Effect of extract of *Phyllanthus niruri* on crystal deposition in experimental urolithiasis. *Urol Res* 34(6):351–357. <https://doi.org/10.1007/s00240-006-0065-1>
69. Christina AJM, Priya Mole M, Moorthy P (2002) Studies on the antilithic effect of *Rotula aquatica* Lour in male Wistar rats. *Methods Find Exp Clin Pharmacol* 24(6):357–359
70. Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T, Sugiyama K (1995) The inhibitory effect of kampo extracts on in vitro calcium oxalate crystallization and in vivo stone formation in an animal model. *Int J Urol* 2(2):81–86
71. Grases F, Ramis M, Costa-Bauzá A, March JG (1995) Effect of *Herniaria hirsuta* and *Agropyron repens* on calcium oxalate urolithiasis risk in rats. *J Ethnopharmacol* 45(3):211–214
72. Varalakshmi P, Shamila Y, Latha E (1990) Effect of *Craeteva nurvala* in experimental urolithiasis. *J Ethnopharmacol* 28(3):313–321
73. Benhelima A, Kaid-Omar Z, Hemida H, Benmahdi T, Addou A (2016) Nephroprotective and Diuretic Effect of *Nigella Sativa* L Seeds Oil on Lithiasic Wistar Rats. *Afr J Tradit Complement Altern Med* 13(6):204–214. <https://doi.org/10.21010/ajtcam.v13i6.30>
74. Nishihata M, Kohjimoto Y, Hara I (2013) Effect of Kampo extracts on urinary stone formation: an experimental investigation. *International journal of urology : official journal of the Japanese Urological Association* 20(10):1032–1036. <https://doi.org/10.1111/iju.12098>
75. Laikangbam R, Damayanti Devi M (2012) Inhibition of calcium oxalate crystal deposition on kidneys of urolithiatic rats by *Hibiscus sabdariffa* L. extract. *Urological research* 40(3):211–218. doi:<https://doi.org/10.1007/s00240-011-0433-3>
76. Soundararajan P, Mahesh R, Ramesh T, Begum VH (2006) Effect of *Aerva lanata* on calcium oxalate urolithiasis in rats. *Indian J Exp Biol* 44(12):981–986
77. Atmani F, Slimani Y, Mimouni M, Aziz M, Hacht B, Ziyayt A (2004) Effect of aqueous extract from *Herniaria hirsuta* L. on experimentally nephrolithiasis rats. *J Ethnopharmacol* 95(1):87–93. doi:<https://doi.org/10.1016/j.jep.2004.06.028>
78. Atmani F, Farell G, Lieske JC (2004) Extract from *Herniaria hirsuta* coats calcium oxalate monohydrate crystals and blocks their adhesion to renal epithelial cells. *J Urol* 172(4 Pt 1):1510–1514. <https://doi.org/10.1097/01.ju.0000131004.03795.c5>
79. Atmani F, Slimani Y, Mimouni M, Hacht B (2003) Prophylaxis of calcium oxalate stones by *Herniaria hirsuta* on experimentally induced nephrolithiasis in rats. *BJU Int* 92(1):137–140. <https://doi.org/10.1046/j.1464-410x.2003.04289.x>
80. Christina AJ, Ashok K, Packialakshmi M, Tobin GC, Preethi J, Muruges N (2005) Antilithiatic effect of *Asparagus racemosus* Willd on ethylene glycol-induced lithiasis in male albino Wistar rats. *Methods Find Exp Clin Pharmacol* 27(9):633–638. <https://doi.org/10.1358/mf.2005.27.9.939338>
81. Akanae W, Tsujihata M, Yoshioka I, Nonomura N, Okuyama A (2010) *Orthosiphon grandiflorum* has a protective effect in a calcium oxalate stone forming rat model. *Urol Res* 38(2):89–96. <https://doi.org/10.1007/s00240-010-0265-6>
82. Tayefi-Nasrabadi H, Sadigh-Eteghad S, Aghdam Z (2012) The effects of the hydroalcohol extract of *Rosa canina* L. fruit on experimentally nephrolithiasis Wistar rats. *Phytother Res* 26(1):78–85. doi:<https://doi.org/10.1002/ptr.3519>
83. Mandavia DR, Patel MK, Patel JC, Anovadiya AP, Baxi SN, Tripathi CR (2013) Anti-urolithiatic effect of ethanolic extract of *Pedaliun murex* Linn. fruits on ethylene glycol-induced renal calculi. *Urol J* 10(3):946–952
84. Patel PK, Patel MA, Vyas BA, Shah DR, Gandhi TR (2012) Antiurolithiatic activity of saponin rich fraction from the fruits of *Solanum xanthocarpum* Schrad. & Wendl. (Solanaceae) against ethylene glycol induced urolithiasis in rats. *J Ethnopharmacol* 144(1):160–170. doi:<https://doi.org/10.1016/j.jep.2012.08.043>
85. Hosseinzadeh H, Khooei AR, Khashayarmanesh Z, Motamed-Shariaty V (2010) Antiurolithiatic activity of *Pinus eldarica* medw: fruits aqueous extract in rats. *Urol J* 7(4):232–237
86. Touhami M, Laroubi A, Elhabazi K, Loubna F, Zrara I, Eljahiri Y, Oussama A, Grases F, Chait A (2007) Lemon juice has

- protective activity in a rat urolithiasis model. *BMC Urol* 7:18. <https://doi.org/10.1186/1471-2490-7-18>
87. Divakar K, Pawar AT, Chandrasekhar SB, Dighe SB, Divakar G (2010) Protective effect of the hydro-alcoholic extract of *Rubia cordifolia* roots against ethylene glycol induced urolithiasis in rats. *Food Chem Toxicol* 48(4):1013–1018. <https://doi.org/10.1016/j.fct.2010.01.011>
  88. Xiang M, Zhang S, Lu J, Li L, Hou W, Xie M, Zeng Y (2011) Antilithic effects of extracts from *Urtica dentata* hand on calcium oxalate urinary stones in rats. *J Huazhong Univ Sci Technolog Med Sci* 31(5):673. <https://doi.org/10.1007/s11596-011-0580-3>
  89. Christina AJM, Packia Lakshmi M, Nagarajan M, Kurian S (2002) Modulatory effect of *Cyclea peltata* Lam. on stone formation induced by ethylene glycol treatment in rats. *Methods Find Exp Clin Pharmacol* 24 (2):77–79
  90. Hadjzadeh MA, Khoei A, Hadjzadeh Z, Parizady M (2007) Ethanol extract of *nigella sativa* L seeds on ethylene glycol-induced kidney calculi in rats. *Urol J* 4(2):86–90
  91. Ilbey YO, Ozbek E, Simsek A, Cekmen M, Somay A, Tasci AI (2009) Effects of pomegranate juice on hyperoxaluria-induced oxidative stress in the rat kidneys. *Ren Fail* 31(6):522–531. <https://doi.org/10.1080/08860220902963871>
  92. Ahsan SK, Tariq M, Ageel AM, al-Yahya MA, Shah AH, (1989) Effect of *Trigonella foenum-graecum* and *Ammi majus* on calcium oxalate urolithiasis in rats. *J Ethnopharmacol* 26(3):249–254
  93. Khan ZA, Assiri AM, Al-Afghani HM, Maghrabi TM (2001) Inhibition of oxalate nephrolithiasis with *Ammi visnaga* (Al-Khillah). *Int Urol Nephrol* 33(4):605–608
  94. Saha S, Verma RJ (2015) Antinephrolithiatic and antioxidative efficacy of *Dolichos biflorus* seeds in a lithiasic rat model. *Pharm Biol* 53(1):16–30. <https://doi.org/10.3109/13880209.2014.909501>
  95. Shah JG, Patel BG, Patel SB, Patel RK (2012) Antiurolithiatic and antioxidant activity of *Hordeum vulgare* seeds on ethylene glycol-induced urolithiasis in rats. *Indian J Pharmacol* 44(6):672–677. <https://doi.org/10.4103/0253-7613.103237>
  96. Sharma I, Khan W, Parveen R, Alam MJ, Ahmad I, Ansari MH, Ahmad S (2017) Antiurolithiasis Activity of Bioactivity Guided Fraction of *Bergenia ligulata* against Ethylene Glycol Induced Renal Calculi in Rat. *Biomed Res Int* 2017:1969525. <https://doi.org/10.1155/2017/1969525>
  97. Saha S, Shrivastav PS, Verma RJ (2014) Antioxidative mechanism involved in the preventive efficacy of *Bergenia ciliata* rhizomes against experimental nephrolithiasis in rats. *Pharm Biol* 52(6):712–722. <https://doi.org/10.3109/13880209.2013.865242>
  98. Saha S, Verma RJ (2011) *Bergenia ciliata* extract prevents ethylene glycol induced histopathological changes in the kidney. *Acta Pol Pharm* 68(5):711–715
  99. Bouanani S, Henchiri C, Migianu-Griffoni E, Aouf N, Lecouvey M (2010) Pharmacological and toxicological effects of *Paronychia argentea* in experimental calcium oxalate nephrolithiasis in rats. *J Ethnopharmacol* 129(1):38–45. <https://doi.org/10.1016/j.jep.2010.01.056>
  100. Zhong YS, Yu CH, Ying HZ, Wang ZY, Cai HF (2012) Prophylactic effects of *Orthosiphon stamineus* Benth. extracts on experimental induction of calcium oxalate nephrolithiasis in rats. *J Ethnopharmacol* 144 (3):761–767. doi:<https://doi.org/10.1016/j.jep.2012.09.052>
  101. Hiremath RD, Jalalpure SS (2016) Effect of hydro-alcoholic extract of *Vernonia cinerea* Less. against ethylene glycol-induced urolithiasis in rats. *Indian J Pharmacol* 48 (4):434–440. doi:<https://doi.org/10.4103/0253-7613.186211>
  102. Nizami AN, Rahman MA, Ahmed NU, Islam MS (2012) Whole *Leea macrophylla* ethanolic extract normalizes kidney deposits and recovers renal impairments in an ethylene glycol-induced urolithiasis model of rats. *Asian Pac J Trop Med* 5(7):533–538. [https://doi.org/10.1016/S1995-7645\(12\)60094-7](https://doi.org/10.1016/S1995-7645(12)60094-7)
  103. Jyothilakshmi V, Thellamudhu G, Kumar A, Khurana A, Nayak D, Kalaiselvi P (2013) Preliminary investigation on ultra high diluted *B. vulgaris* in experimental urolithiasis. *Homeopathy* 102 (3):172–178. doi:<https://doi.org/10.1016/j.homp.2013.05.004>
  104. Onaran M, Orhan N, Farahvash A, Ekin HN, Kocabiyik M, Gonul II, Sen I, Aslan M (2016) Successful treatment of sodium oxalate induced urolithiasis with *Helichrysum* flowers. *J Ethnopharmacol* 186:322–328. <https://doi.org/10.1016/j.jep.2016.04.003>
  105. Siddiqui WA, Shahzad M, Shabbir A, Ahmad A (2018) Evaluation of anti-urolithiatic and diuretic activities of watermelon (*Citrullus lanatus*) using in vivo and in vitro experiments. *Biomed Pharmacother* 97:1212–1221. <https://doi.org/10.1016/j.biopha.2017.10.162>
  106. Sahin C, Sarikaya S, Basak K, Cetinel CA, Narter F, Eryildirim B, Saglam E, Sarica K (2015) Limitation of apoptotic changes and crystal deposition by Tutukon following hyperoxaluria-induced tubular cell injury in rat model. *Urolithiasis* 43(4):313–322. <https://doi.org/10.1007/s00240-015-0777-1>
  107. Cho HJ, Bae WJ, Kim SJ, Hong SH, Lee JY, Hwang TK, Choi YJ, Hwang SY, Kim SW (2014) The inhibitory effect of an ethanol extract of the spores of *Lygodium japonicum* on ethylene glycol-induced kidney calculi in rats. *Urolithiasis* 42(4):309–315. <https://doi.org/10.1007/s00240-014-0674-z>
  108. Youn SH, Kwon JH, Yin J, Tam LT, Ahn HS, Myung SC, Lee MW (2017) Anti-Inflammatory and Anti-Urolithiasis Effects of Polyphenolic Compounds from *Quercus gilva* Blume. *Molecules* 22 (7). doi:<https://doi.org/10.3390/molecules22071121>
  109. Prabhu VV, Sathyamurthy D, Ramasamy A, Das S, Anuradha M, Pachappan S (2016) Evaluation of protective effects of diosmin (a citrus flavonoid) in chemical-induced urolithiasis in experimental rats. *Pharm Biol* 54(9):1513–1521. <https://doi.org/10.3109/13880209.2015.1107105>
  110. Bodakhe KS, Namdeo KP, Patra KC, Machwal L, Pareta SK (2013) A polyherbal formulation attenuates hyperoxaluria-induced oxidative stress and prevents subsequent deposition of calcium oxalate crystals and renal cell injury in rat kidneys. *Chin J Nat Med* 11(5):466–471. [https://doi.org/10.1016/S1875-5364\(13\)60085-0](https://doi.org/10.1016/S1875-5364(13)60085-0)
  111. Grases F, Prieto RM, Gomila I, Sanchis P, Costa-Bauza A (2009) Phytotherapy and renal stones: the role of antioxidants. A pilot study in Wistar rats. *Urological research* 37 (1):35–40. doi:<https://doi.org/10.1007/s00240-008-0165-1>
  112. Tsai CH, Chen YC, Chen LD, Pan TC, Ho CY, Lai MT, Tsai FJ, Chen WC (2008) A traditional Chinese herbal antilithic formula, *Wulingsan*, effectively prevents the renal deposition of calcium oxalate crystal in ethylene glycol-fed rats. *Urol Res* 36(1):17–24. <https://doi.org/10.1007/s00240-007-0122-4>
  113. Ogawa Y, Morozumi M, Tanaka T, Yamaguchi K (1986) A comparison between effects of pyruvate and herb medicines in preventing experimental oxalate urolithiasis in rats. *Hinyokika Kyo* 32(8):1127–1133
  114. Yasui T, Fujita K, Sato M, Sugimoto M, Iguchi M, Nomura S, Kohri K (1999) The effect of takusha, a kampo medicine, on renal stone formation and osteopontin expression in a rat urolithiasis model. *Urol Res* 27(3):194–199
  115. Yamaguchi S, Jihong L, Utsunomiya M, Yoshioka T, Okuyama A, Koide T, Sugiyama K (1995) The effect of takusha and kagosou on calcium oxalate renal stones in rats. *Hinyokika Kyo* 41(6):427–431
  116. Tsai CH, Pan TC, Lai MT, Lee SC, Chen ML, Jheng JR, Chen WC (2009) Prophylaxis of experimentally induced calcium oxalate nephrolithiasis in rats by *Zhulingtang*, a traditional

- Chinese herbal formula. *Urol Int* 82(4):464–471. <https://doi.org/10.1159/000218539>
117. Jagannath N, Chikkannasetty SS, Govindadas D, Devasankaraiah G (2012) Study of antiurolithiatic activity of *Asparagus racemosus* on albino rats. *Indian J Pharmacol* 44(5):576–579. <https://doi.org/10.4103/0253-7613.100378>
  118. Liang Q, Li X, Zhou W, Su Y, He S, Cheng S, Lu J, Cao W, Yan Y, Pei X, Qi J, Xu G, Yue Z (2016) An Explanation of the Underlying Mechanisms for the In Vitro and In Vivo Antiurolithic Activity of *Glechoma longituba*. *Oxid Med Cell Longev* 2016:3134919. <https://doi.org/10.1155/2016/3134919>
  119. Lin WC, Lai MT, Chen HY, Ho CY, Man KM, Shen JL, Lee YJ, Tsai FJ, Chen YH, Chen WC (2012) Protective effect of *Flos carthami* extract against ethylene glycol-induced urolithiasis in rats. *Urol Res* 40(6):655–661. <https://doi.org/10.1007/s00240-012-0472-4>
  120. Gandhi M, Aggarwal M, Puri S, Singla SK (2013) Prophylactic effect of coconut water (*Cocos nucifera* L.) on ethylene glycol induced nephrocalcinosis in male wistar rat. *Int Braz J Urol* 39(1):108–117. doi:<https://doi.org/10.1590/S1677-5538.IBJU.2013.01.14>
  121. Hirayama H, Wang Z, Nishi K, Ogawa A, Ishimatu T, Ueda S, Kubo T, Nohara T (1993) Effect of *Desmodium styracifolium*-triterpenoid on calcium oxalate renal stones. *Br J Urol* 71(2):143–147. <https://doi.org/10.1111/j.1464-410x.1993.tb15906.x>
  122. Khan SR (1997) Animal models of kidney stone formation: an analysis. *World J Urol* 15(4):236–243
  123. Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, Traxer O, Tiselius HG (2016) Kidney stones Nature reviews Disease primers 2:16008. <https://doi.org/10.1038/nrdp.2016.8>
  124. Robertson WG (2017) Do “inhibitors of crystallisation” play any role in the prevention of kidney stones? A critique *Urolithiasis* 45(1):43–56. <https://doi.org/10.1007/s00240-016-0953-y>
  125. Robertson WG (2004) Kidney models of calcium oxalate stone formation. *Nephron Physiology* 98(2):p21-30. <https://doi.org/10.1159/000080260>
  126. Rodgers AL (2017) Physicochemical mechanisms of stone formation. *Urolithiasis* 45(1):27–32. <https://doi.org/10.1007/s00240-016-0942-1>
  127. Khan SR, Kok DJ (2004) Modulators of urinary stone formation. *Front Biosci* 9(14977559):1450–1482. <https://doi.org/10.2741/1347>
  128. Khan SR, Canales BK (2015) Unified theory on the pathogenesis of Randall’s plaques and plugs. *Urolithiasis* 43(1):109–123. <https://doi.org/10.1007/s00240-014-0705-9>
  129. Linnes MP, Krambeck AE, Cornell L, Williams JC Jr, Korinek M, Bergstralh EJ, Li X, Rule AD, McCollough CM, Vrtiska TJ, Lieske JC (2013) Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. *Kidney Int* 84(4):818–825. <https://doi.org/10.1038/ki.2013.189>
  130. Verkoelen CF, van der Boom BG, Schroder FH, Romijn JC (1997) Cell cultures and nephrolithiasis. *World J Urol* 15(4):229–235
  131. Kavanagh JP (2006) In vitro calcium oxalate crystallisation methods. *Urol Res* 34(2):139–145. <https://doi.org/10.1007/s00240-005-0027-z>
  132. Hennequin C, Lalanne V, Daudon M, Lacour B, Druke T (1993) A new approach to studying inhibitors of calcium oxalate crystal growth. *Urol Res* 21(2):101–108
  133. Hess B, Meinhardt U, Zipperle L, Giovanoli R, Jaeger P (1995) Simultaneous measurements of calcium oxalate crystal nucleation and aggregation: impact of various modifiers. *Urol Res* 23(4):231–238
  134. Khan A (2018) In vitro and in vivo models for the study of urolithiasis. *Urologia* 85(4):145–149. <https://doi.org/10.1177/0391560317751578>
  135. Khan SR (2010) Nephrocalcinosis in animal models with and without stones. *Urol Res* 38(6):429–438. <https://doi.org/10.1007/s00240-010-0303-4>
  136. Davis CM (2013) Animal Models of Drug Abuse: Place and Taste Conditioning. In: *Animal Models for the Study of Human Disease*. Elsevier Inc, pp 681–707
  137. Khan SR (2013) Animal Models of Calcium Oxalate Kidney Stone Formation. In: Conn PM (ed) *Animal models for the study of human disease*. Academic Press, pp 483–498
  138. Thamilselvan S, Hackett RL, Khan SR (1997) Lipid peroxidation in ethylene glycol induced hyperoxaluria and calcium oxalate nephrolithiasis. *J Urol* 157(3):1059–1063
  139. Thamilselvan S, Menon M (2005) Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. *BJU Int* 96(1):117–126. <https://doi.org/10.1111/j.1464-410x.2005.05579.x>
  140. Fan J, Glass MA, Chandhoke PS (1999) Impact of ammonium chloride administration on a rat ethylene glycol urolithiasis model. *Scanning Microsc* 13(2–3):299–306
  141. Khan SR, Glenton PA (1995) Deposition of calcium phosphate and calcium oxalate crystals in the kidneys. *J Urol* 153(3 Pt 1):811–817
  142. Hackett RL, Shevock PN, Khan SR (1990) Cell injury associated calcium oxalate crystalluria. *J Urol* 144(6):1535–1538
  143. Tawashi R, Cousineau M, Sharkawi M (1980) Calcium oxalate crystal formation in the kidneys of rats injected with 4-hydroxy-L-proline. *Urol Res* 8(2):121–127. <https://doi.org/10.1007/BF00271440>
  144. Bushinsky DA, Favus MJ (1988) Mechanism of hypercalciuria in genetic hypercalciuric rats. Inherited defect in intestinal calcium transport. *The Journal of clinical investigation* 82(5):1585–1591. doi:<https://doi.org/10.1172/jci113770>
  145. Bushinsky DA (1999) Genetic hypercalciuric stone-forming rats. *Curr Opin Nephrol Hypertens* 8(4):479–488
  146. Khan SR, Finlayson B, Hackett R (1982) Experimental calcium oxalate nephrolithiasis in the rat. Role of the renal papilla. *The American journal of pathology* 107(1):59
  147. Ogawa Y, Yamaguchi K, Morozumi M (1990) Effects of magnesium salts in preventing experimental oxalate urolithiasis in rats. *The Journal of Urology* 144(2 Pt 1):385–389
  148. Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG (2003) Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. *J Am Soc Nephrol* 14(1):139–147
  149. Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. *Kidney Int* 66(3):1159–1166
  150. Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Notoli TP, Binder HJ, Aronson PS (2006) Calcium oxalate urolithiasis in mice lacking anion transporter *Slc26a6*. *Nat Genet* 38(4):474–478. <https://doi.org/10.1038/ng1762>
  151. Weinman EJ, Mohanlal V, Stoycheff N, Wang F, Steplock D, Shenolikar S, Cunningham R (2006) Longitudinal study of urinary excretion of phosphate, calcium, and uric acid in mutant *NHERF-1* null mice. *Am J Physiol Renal Physiol* 290(4):F838–843. <https://doi.org/10.1152/ajprenal.00374.2005>
  152. Tzou DT, Taguchi K, Chi T, Stoller ML (2016) Animal models of urinary stone disease. *Int J Surg* 36(Pt D):596–606. <https://doi.org/10.1016/j.ijssu.2016.11.018>

153. Okada Y, Kawamura J, Nonomura M, Kuo YJ, Yoshida O (1985) Experimental and clinical studies on calcium urolithiasis: (I) Animal model for calcium oxalate urolithiasis using ethylene glycol and 1-alpha (OH) D3. *Hinyokika Kiyo* 31(4):565–577
154. Ozturk H, Ozturk H, Yagmur Y, Buyukbayram H (2006) The effect of L-arginine methyl ester on indices of free radical involvement in a rat model of experimental nephrocalcinosis. *Urol Res* 34(5):305–314. <https://doi.org/10.1007/s00240-006-0061-5>
155. Miller J, Chi T, Kapahi P, Kahn AJ, Kim MS, Hirata T, Romero MF, Dow JA, Stoller ML (2013) *Drosophila melanogaster* as an emerging translational model of human nephrolithiasis. *J Urol* 190(5):1648–1656. <https://doi.org/10.1016/j.juro.2013.03.010>
156. Chen YH, Liu HP, Chen HY, Tsai FJ, Chang CH, Lee YJ, Lin WY, Chen WC (2011) Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a *Drosophila* model for nephrolithiasis/urolithiasis. *Kidney Int* 80(4):369–377. <https://doi.org/10.1038/ki.2011.80>
157. Mandel NS, Henderson JD Jr, Hung LY, Wille DF, Wiessner JH (2004) A porcine model of calcium oxalate kidney stone disease. *J Urol* 171(3):1301–1303. <https://doi.org/10.1097/01.ju.0000110101.41653.bb>
158. Penniston KL, Patel SR, Schwahn DJ, Nakada SY (2017) Studies using a porcine model: what insights into human calcium oxalate stone formation mechanisms has this model facilitated? *Urolithiasis* 45(1):109–125. <https://doi.org/10.1007/s00240-016-0947-9>
159. Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. *J Urol* 189(3):803–811. <https://doi.org/10.1016/j.juro.2012.05.078>
160. Khan SR (2014) Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. *Translational andrology and urology* 3(3):256–276. <https://doi.org/10.3978/j.issn.2223-4683.2014.06.04>
161. Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. *Urol Res* 33(5):349–357. <https://doi.org/10.1007/s00240-005-0492-4>
162. Khan SR, Joshi S, Wang W, Peck AB (2014) Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria. *Am J Physiol Renal Physiol* 306(11):F1285–1295. <https://doi.org/10.1152/ajprenal.00057.2014>
163. Joshi S, Clapp WL, Wang W (1852) Khan SR (2015) Osteogenic changes in kidneys of hyperoxaluric rats. *Biochem Biophys Acta* 9:2000–2012. <https://doi.org/10.1016/j.bbdis.2015.06.020>
164. Joshi S, Khan SR (2019) NADPH oxidase: a therapeutic target for hyperoxaluria-induced oxidative stress - an update. *Future medicinal chemistry* 11(23):2975–2978. <https://doi.org/10.4155/fmc-2019-0275>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.